Trevena said Thursday it has reduced its workforce by about 25% as part of a "resource realignment" that will allow it to extend its cash runway into mid-2023.
The Chesterbrook biopharmaceutical company started the year with 43 employees, which means jobs cuts will impact 10 or 11 positions.
Trevena (NASDAQ: TRVN) said it also terminated its contract sales force agreement with Syneos.
The company will maintain a "focused internal commercial and medical affairs team" to support its flagship product…
